The Pathogenesis of Ebola Virus Disease∗

Annual Review of Pathology: Mechanisms of Disease

Volumn 12, Issue , 2017, Pages 387-418

  Baseler, Laura ^a   Chertow, Daniel S ^b   Johnson, Karl M ^c   Feldmann, Heinz ^b   Morens, David M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Ebola; Ebolavirus; Epidemic; Filovirus; Viral disease pathogenesis; Viral hemorrhagic fever

Indexed keywords

ANTIVIRUS AGENT; EBOLA VACCINE;

CASE FATALITY RATE; CLINICAL OBSERVATION; CONCURRENT INFECTION; CONVALESCENCE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE TRANSMISSION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; GUINEA PIG; HUMAN; IMMUNE EVASION; INCIDENCE; INTENSIVE CARE UNIT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PHYLOGENY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYRIAN HAMSTER; TISSUE INJURY; VIRAL TROPISM; CLASSIFICATION; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; ISOLATION AND PURIFICATION; PATHOGENICITY; PATHOLOGY; TRANSMISSION;

DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 85011277617     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-052016-100506     Document Type: Review

References (179)

1. WHO(WorldHealth Organ.) Ebola Response Team. 2016. After Ebola inWest Africa-unpredictable risks, preventable epidemics. N. Engl. J. Med. 375:587-96
2. WHO(WorldHealthOrgan.) 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 56:271-93
3. McCormick JB, Bauer SP, Elliott LH, Webb PA, Johnson KM. 1983. Biologic differences between strains of Ebola virus from Zaire and Sudan. J. Infect. Dis. 147:264-67
4. Richman DD, Cleveland PH, McCormick JB, Johnson KM. 1983. Antigenic analysis of strains of Ebola virus: identification of two Ebola virus serotypes. J. Infect. Dis. 147:268-71
5. Breman JG, Johnson KM, van der Groen G, Robbins CB, Szczeniowski MV, et al. 1999. A search for Ebola virus in animals in the Democratic Republic of the Congo and Cameroon: ecologic, virologic, and serologic surveys, 1979-1980. Ebola Virus Study Teams. J. Infect. Dis. 179(Suppl. 1):S139-47
6. Peterson AT, Carroll DS,Mills JN, Johnson KM. 2004. Potential mammalian filovirus reservoirs. Emerg. Infect. Dis. 10:2073-81
7. Burk RBL, Bollinger L, Johnson JC,Wada J, Radoshitzky SR, et al. 2016. Neglected filoviruses. FEMS Microbiol. Rev. 40:1-26
8. Feldman HSA, Geisbert TW. 2013. Filoviridae: Marburg and Ebola viruses. In Fields Virology, ed.DM Knipe, PM Howley, pp. 923-56. Philadelphia: Wolters Kluwer Health/LippincottWilliams &Wilkins. 6th ed
9. Kuhn J, Becker S, Ebihara H, Geisbert TW, Jahrling PB, et al. 2011. Family Filoviridae. In Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses, ed. AMQ King, MJ Adams, EB Carstens, et al., pp. 655-71. London: Elsevier
10. Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H, et al. 2011. Discovery of an ebolavirus-like filovirus in Europe. PLOS Pathog. 7:e1002304
11. Hoenen T, Feldmann H. 2014. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev. Anti Infect. Ther. 12:1253-63
12. Banadyga L, Dolan MA, Ebihara H. 2016. Rodent-adapted filoviruses and the molecular basis of pathogenesis. J. Mol. Biol. 428:3449-66
13. Muhlberger E. 2007. Filovirus replication and transcription. Future Virol. 2:205-15
14. Basler CF. 2015. Innate immune evasion by filoviruses. Virology 479-480:122-30
15. Messaoudi I, Amarasinghe GK, Basler CF. 2015. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13:663-76
16. Basler CF. 2013. A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein. Expert Rev. Anti Infect. Ther. 11:475-78
17. Gire SK,Goba A, Andersen KG, Sealfon RS, Park DJ, et al. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369-72
18. Groseth A, Feldmann H, Strong JE. 2007. The ecology of Ebola virus. Trends Microbiol. 15:408-16
19. Lam TT, Zhu H, Chong YL, Holmes EC, Guan Y. 2015. Puzzling origins of the Ebola outbreak in the Democratic Republic of the Congo, 2014. J. Virol. 89:10130-32
20. Georges-Courbot MC, Sanchez A, Lu CY, Baize S, Leroy E, et al. 1997. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg. Infect. Dis. 3:59-62
21. Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA, et al. 2015. Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348:117-19
22. Viana M, Mancy R, Biek R, Cleaveland S, Cross PC, et al. 2014. Assembling evidence for identifying reservoirs of infection. Trends Ecol. Evol. 29:270-79
23. Plowright RK, Eby P, Hudson PJ, Smith IL, Westcott D, et al. 2015. Ecological dynamics of emerging bat virus spillover. Proc. Biol. Sci. 282:20142124
24. Strong JE, Wong G, Jones SE, Grolla A, Theriault S, et al. 2008. Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. PNAS 105:17982-87
25. Leendertz SAJ, Gogarten JF, Dux A, Calvignac-Spencer S, Leendertz FH. 2015. Assessing the evidence supporting fruit bats as the primary reservoirs for Ebola viruses. Ecohealth 13:18-25
26. Pourrut X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM. 2007. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J. Infect. Dis. 196(Suppl. 2):S176-83
27. JonesMEB, Schuh AJ, Amman BR, Sealy TK, Zaki SR, et al. 2015. Experimental inoculation of Egyptian rousette bats (Rousettus aegyptiacus)with viruses of the Ebolavirus and Marburgvirus genera. Viruses 7:3420-42
28. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, et al. 2009. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. 9:723-28
29. Olival KJ, Hayman DT. 2014. Filoviruses in bats: current knowledge and future directions. Viruses 6:1759-88
30. Wahl-Jensen VRS, Kok-Mercado F. 2014. Role of rodents and bats in human viral hemorrhagic fevers. In Viral Hemorrhagic Fevers, ed. SKRD Singh, pp. 99-127. Boca Raton, FL: CRC Press
31. Pigott DM, Golding N, Mylne A,Huang Z, Henry AJ, et al. 2014. Mapping the zoonotic niche of Ebola virus disease in Africa. eLife 3:e04395
32. Cent. Dis. Control Prev. 2016. Outbreaks chronology: Ebola virus disease. April 14 http://www.cdc.gov/ vhf/ebola/outbreaks/history/chronology.html
33. Glynn JR. 2015. Age-specific incidence of Ebola virus disease. Lancet 386:432
34. Dean NE, Halloran ME, Yang Y, Longini IM. 2016. Transmissibility and pathogenicity of Ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin. Infect. Dis. 62:1277-86
35. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, et al. 1999. The reemergence of Ebola hemorrhagic fever,DemocraticRepublic of theCongo, 1995.Commission deLutte contre lesÉpidémiesa Kikwit. J. Infect. Dis. 179(Suppl. 1):S76-86
36. Fischer R, Judson S, Miazgowicz K, Bushmaker T, Prescott J, Munster VJ. 2015. Ebola virus stability on surfaces and in fluids in simulated outbreak environments. Emerg. Infect. Dis. 21:1243-46
37. Ajelli M, Parlamento S, Bome D, Kebbi A, Atzori A, et al. 2015. The 2014 Ebola virus disease outbreak in Pujehun, Sierra Leone: epidemiology and impact of interventions. BMC Med. 13:281
38. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. 1999. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Épidémies aKikwit. J. Infect. Dis. 179(Suppl. 1):S87-91
39. Bower H, Johnson S, Bangura MS, Kamara AJ, Kamara O, et al. 2016. Exposure-specific and agespecific attack rates for Ebola virus disease in Ebola-affected households, Sierra Leone. Emerg. Infect. Dis. 22:1403-11
40. Nielsen CF, Kidd S, Sillah AR, Davis E, Mermin J, Kilmarx PH. 2015. Improving burial practices and cemetery management during an Ebola virus disease epidemic-Sierra Leone, 2014. Morb.Mortal.Wkly. Rep. 64:20-27
41. Lokuge K, Caleo G, Greig J, Duncombe J, McWilliam N, et al. 2016. Successful control of Ebola virus disease: analysis of service based data from rural Sierra Leone. PLOS Negl. Trop. Dis. 10:e0004498
42. Johnson E, Jaax N, White J, Jahrling P. 1995. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76:227-36
43. Zumbrun EE, Bloomfield HA, Dye JM, Hunter TC, Dabisch PA, et al. 2012. A characterization of aerosolized Sudan virus infection inAfrican green monkeys, cynomolgusmacaques, and rhesusmacaques. Viruses 4:2115-36
44. Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, et al. 2011. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J. Infect. Dis. 204:200-8
45. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. 2011. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 13:930-36
46. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. 2012. Transmission of Ebola virus from pigs to non-human primates. Sci. Rep. 2:811
47. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163:2347-70
48. Edwards JK, Kleine C, Munster V, Giuliani R, Massaquoi M, et al. 2015. Interpretation of negative molecular test results in patients with suspected or confirmed Ebola virus disease: report of two cases. Open Forum Infect. Dis. 2:ofv137
49. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, et al. 2015. Blood kinetics of Ebola virus in survivors and nonsurvivors. J. Clin. Invest. 125:4692-98
50. Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB, et al. 1997. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch. Pathol. Lab. Med. 121:805-19
51. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. 2015. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J. Pathol. 235:153-74
52. Yen B, Mulder LC, Martinez O, Basler CF. 2014. Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J. Virol. 88:12500-10
53. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, et al. 2000. The Ebola virus VP35 protein functions as a type I IFN antagonist. PNAS 97:12289-94
54. LeungDW,Prins KC, Basler CF, AmarasingheGK.2010. Ebolavirus VP35 is amultifunctional virulence factor. Virulence 1:526-31
55. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, et al. 2006. Ebola virus VP24 binds karyopherin α1 and blocks STAT1 nuclear accumulation. J. Virol. 80:5156-67
56. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, et al. 2014. Ebola virus VP24 targets a unique NLS-binding site on karyopherin5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16:187-200
57. Zhang AP, Abelson DM, Bornholdt ZA, Liu T,Woods VL Jr., Saphire EO. 2012. The ebolavirus VP24 interferon antagonist: Know your enemy. Virulence 3:440-45
58. Ansari AA. 2014. Clinical features and pathobiology of Ebolavirus infection. J. Autoimmun. 55:1-9
59. ZhangAP, Bornholdt ZA, LiuT,AbelsonDM,Lee DE, et al. 2012. TheEbola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLOS Pathog. 8:e1002550
60. CardenasWB, Loo YM, GaleMJr., Hartman AL, Kimberlin CR, et al. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80:5168-78
61. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, et al. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945-56
62. LeungDW,Ginder ND, FultonDB, Nix J, BaslerCF, et al. 2009. Structure of the EbolaVP35 interferon inhibitory domain. PNAS 106:411-16
63. Leung LW, Park MS,Martinez O, Valmas C, Lopez CB, Basler CF. 2011. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol. Cell Biol. 89:792-802
64. JinH, Yan Z, Prabhakar BS, Feng Z, Ma Y, et al. 2010. TheVP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J. Gen. Virol. 91:352-61
65. Ito H, Watanabe S, Takada A, Kawaoka Y. 2001. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75:1576-80
66. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, Bates P. 2010. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLOS Pathog. 6:e1001098
67. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, et al. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 78:10370-77
68. Zaki SR, Goldsmith CS. 1999. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 235:97-116
69. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. 2003. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188:1618-29
70. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. 2010. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and withmassive lymphocyte apoptosis. PLOS Negl. Trop. Dis. 4:e837
71. GuptaM, Spiropoulou C, Rollin PE. 2007. Ebola virus infection of human PBMCs causesmassive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364:45-54
72. Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, et al. 2010. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J. Immunol. 184:327-35
73. Hensley LE, YoungHA, Jahrling PB, Geisbert TW. 2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80:169-79
74. Rasmussen AL. 2016. Host factors in Ebola infection. Annu. Rev. Genom. Hum. Genet. 17:333-51
75. WHO (World Health Organ.) Int. Study Team. 1978. Ebola haemorrhagic fever in Sudan, 1976. Bull. World Health Organ. 56:247-70
76. Zaki SR, Shieh WJ, Greer PW, Goldsmith CS, Ferebee T, et al. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémiesa Kikwit. J. Infect. Dis. 179(Suppl. 1):S36-47
77. Sureau PH. 1989. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev. Infect. Dis. 11(Suppl. 4):S790-93
78. Dietrich M, Schumacher HH, Peters D, Knobloch J. 1978. Human pathology of Ebola (Maridi) virus infection in the Sudan. In Ebola Virus Haemorrhagic Fever, ed. SR Pattyn, pp. 37-41. Amsterdam: Elsevier
79. Murphy FA. 1978. Pathology of Ebola virus infection. In Ebola Virus Haemorrhagic Fever, ed. SR Pattyn, pp. 43-59. Amsterdam: Elsevier
80. Ellis DS, Simpson IH, Francis DP, Knobloch J, Bowen ET, et al. 1978. Ultrastructure of Ebola virus particles in human liver. J. Clin. Pathol. 31:201-8
81. Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, et al. 1999. Ebola hemorrhagic fever in Kikwit, Democratic Republic of theCongo: clinical observations in 103 patients. J. Infect. Dis. 179(Suppl. 1):S1-7
82. Rollin PE, Bausch DG, Sanchez A. 2007. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J. Infect. Dis. 196(Suppl. 2):S364-71
83. TwenhafelNA, MattixME, Johnson JC,Robinson CG, PrattWD,et al. 2013. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet. Pathol. 50:514-29
84. Cournac JM, Karkowski L, Bordes J, Aletti M, Duron S, et al. 2016. Rhabdomyolysis in Ebola virus disease. Results of an observational study in a treatment center in Guinea. Clin. Infect. Dis. 62:19-23
85. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, et al. 2015. Persistence of Ebola virus in ocular fluid during convalescence. N. Engl. J. Med. 372:2423-27
86. Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, et al. 1999. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J. Infect. Dis. 179(Suppl. 1):S13-14
87. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, et al. 2015. Ebola RNA persistence in semen of Ebola virus disease survivors-preliminary report. N. Engl. J. Med. https://doi.org/10.1056/ NEJMoa1511410
88. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, et al. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179(Suppl. 1):S170-76
89. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. 2000. Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278:20-26
90. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6:886-89
91. Villinger F, Rollin PE, Brar SS, Chikkala NF,Winter J, et al. 1999. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J. Infect. Dis. 179(Suppl. 1):S188-91
92. Edwards KM, Davis JE, Browne KA, Sutton VR, Trapani JA. 1999. Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction. Immunol. Cell Biol. 77:76-89
93. Topham NJ,Hewitt EW. 2009. Natural killer cell cytotoxicity:Howdo they pull the trigger? Immunology 128:7-15
94. Palmer RM, Bridge L, Foxwell NA,Moncada S. 1992. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br. J. Pharmacol. 105:11-12
95. Wei T, Chen C, Hou J, Xin W, Mori A. 2000. Nitric oxide induces oxidative stress and apoptosis in neuronal cells. Biochim. Biophys. Acta 1498:72-79
96. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, et al. 1997. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler. Thromb. Vasc. Biol. 17:3399-405
97. Nemerson Y. 1988. Tissue factor and hemostasis. Blood 71:1-8
98. Conway EM, Rosenberg RD. 1988. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell Biol. 8:5588-92
99. Mammen EF. 1992. Coagulation abnormalities in liver disease. Hematol. Oncol. Clin. North Am. 6:1247-57
100. Taylor FB Jr., Toh CH, HootsWK, Wada H, Levi M. 2001. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86:1327-30
101. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70:2208-14
102. Jerca L, Jerca O, Mancas G, Constantinescu I, Lupusoru R. 2002. Mechanism of action and biochemical effects of nitric oxide (NO). J. Prev. Med. 10:35-45
103. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-61
104. Bray M. 2001. The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82:1365-73
105. Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, et al. 2006. Molecular determinants of Ebola virus virulence in mice. PLOS Pathog. 2:e73
106. Bray M, Hatfill S, Hensley L,Huggins JW. 2001. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 125:243-53
107. Rasmussen AL, Okumura A, FerrisMT, Green R, Feldmann F, et al. 2014. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346:987-91
108. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD. 2000. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277:147-55
109. Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW. 2015. Modeling the disease course of Zaire ebolavirus infection in the outbred guinea pig. J. Infect. Dis. 212(Suppl. 2):S305-15
110. Connolly BM, Steele KE, Davis KJ, Geisbert TW, KellWM, et al. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179(Suppl. 1):S203-17
111. Ryabchikova E, Kolesnikova L, Smolina M, Tkachev V, Pereboeva L, et al. 1996. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch. Virol. 141:909-21
112. Ebihara H, Zivcec M, Gardner D, Falzarano D, LaCasse R, et al. 2013. A Syrian golden hamster model recapitulating Ebola hemorrhagic fever. J. Infect. Dis. 207:306-18
113. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. 1978. The pathology of experimental Ebola virus infection in monkeys. J. Pathol. 125:131-38
114. Ryabchikova EI, Kolesnikova LV, Luchko SV. 1999. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179(Suppl. 1):S199-202
115. Carrion R Jr., Ro Y, Hoosien K, Ticer A, Brasky K, et al. 2011. A small nonhuman primate model for filovirus-induced disease. Virology 420:117-24
116. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, et al. 1996. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med. 120:140-55
117. Alves DA, Honko AN, Kortepeter MG, Sun M, Johnson JC, et al. 2016. Necrotizing scleritis, conjunctivitis, and other pathologic findings in the left eye and brain of an Ebola virus-infected rhesus macaque (Macaca mulatta) with apparent recovery and a delayed time of death. J. Infect. Dis. 213:57-60
118. Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW. 2005. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooue-Ivindo region, Northeastern Gabon, 1997. J. Infect. Dis. 191:964-68
119. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, et al. 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355:2210-15
120. Akerlund E, Prescott J, Tampellini L. 2015. Shedding of Ebola virus in an asymptomatic pregnant woman. N. Engl. J. Med. 372:2467-69
121. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, et al. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med. 371:2092-100
122. Faye O, Andronico A, Faye O, Salje H, Boelle PY, et al. 2015. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLOS Med. 12:e1001908
123. de La Vega MA, Caleo G, Audet J, Qiu X, Kozak RA, et al. 2015. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J. Clin. Invest. 125:4421-28
124. Li J, Duan HJ, Chen HY, Ji YJ, Zhang X, et al. 2016. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int. J. Infect. Dis. 42:34-39
125. Chertow DS, Kleine C, Edwards JK, Scaini R, Giuliani R, Sprecher A. 2014. Ebola virus disease inWest Africa-clinical manifestations and management. N. Engl. J. Med. 371:2054-57
126. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, et al. 2014. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 371:2402-9
127. Chertow DS, Uyeki TM, DuPont HL. 2015. Loperamide therapy for voluminous diarrhea in Ebola virus disease. J. Infect. Dis. 211:1036-37
128. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, et al. 2015. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 15:1292-99
129. Uyeki TM, Mehta AK, Davey RT Jr., Liddell AM,Wolf T, et al. 2016. Clinical management of Ebola virus disease in the United States and Europe. N. Engl. J. Med. 374:636-46
130. McElroy AK, Akondy RS,Davis CW, Ellebedy AH,Mehta AK, et al. 2015. Human Ebola virus infection results in substantial immune activation. PNAS 112:4719-24
131. Wolf T, Kann G, Becker S, Stephan C, Brodt HR, et al. 2015. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385:1428-35
132. Russo T, Costa C, Crujo C, Lopes AI. 2012. Protein-losing gastropathy associated with cytomegalovirus infection in a child. BMJ Case Rep. 2012:bcr0120125679
133. Megged O, Schlesinger Y. 2008. Cytomegalovirus-associated protein-losing gastropathy in childhood. Eur. J. Pediatr. 167:1217-20
134. Zivin JR, Gooley T, Zager RA, Ryan MJ. 2001. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am. J. Kidney Dis. 37:689-98
135. Chertow DS, Nath A, Suffredini AF, Danner RL, Reich DS, et al. 2016. Severe meningoencephalitis in a case of Ebola virus disease: a case report. Ann. Intern. Med. 165:301-4
136. Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, et al. 2014. A case of severe Ebola virus infection complicated by gram-negative septicemia. N. Engl. J. Med. 371:2394-401
137. Liddell AM, Davey RT Jr., Mehta AK, Varkey JB, Kraft CS, et al. 2015. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann. Intern. Med. 163:81-90
138. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, et al. 1999. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémiesa Kikwit. J. Infect. Dis. 179(Suppl. 1):S28-35
139. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, et al. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179(Suppl. 1):S177-87
140. Howlett P, Brown C, Helderman T, Brooks T, Lisk D, et al. 2016. Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. Emerg. Infect. Dis. 22:150-52
141. Bechtelsheimer H, Korb G, Gedigk P. 1970. The "Marburg-virus"-hepatitis. Studies in man and guinea pigs. Virchows Arch. A Pathol. Anat. Histol. 351:273-90
142. SlenczkaWG. 1999. TheMarburg virus outbreak of 1967 and subsequent episodes. Curr. Top. Microbiol. Immunol. 235:49-75
143. Larsen T, Stevens EL, Davis KJ, Geisbert JB, Daddario-DiCaprio KM, et al. 2007. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J. Infect. Dis. 196(Suppl. 2):S323-28
144. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, et al. 2015. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 61:496-502
145. Connor MJ Jr., Kraft C, Mehta AK, Varkey JB, Lyon GM, et al. 2015. Successful delivery of RRT in Ebola virus disease. J. Am. Soc. Nephrol. 26:31-37
146. KortepeterMG,Bausch DG, Bray M. 2011. Basic clinical and laboratory features of filoviral hemorrhagic fever. J. Infect. Dis. 204(Suppl. 3):S810-16
147. Chertow DSCR, Arai AE, Davey RT. 2016. Cardiac MRI findings suggest myocarditis in severe Ebola virus disease. JACC Cardiovasc. Imaging. http://dx.doi.org/10.1016/j.jcmg.2016.06.004. In press
148. Lazzerini PE, Capecchi PL, Laghi-Pasini F. 2015. Long QT syndrome: an emerging role for inflammation and immunity. Front. Cardiovasc. Med. 2:26
149. de Wit E, Falzarano D, Onyango C, Rosenke K, Marzi A, et al. 2016. The merits of malaria diagnostics during an Ebola virus disease outbreak. Emerg. Infect. Dis. 22:323-26
150. Mupapa K, Mukundu W, Bwaka MA, Kipasa M, De Roo A, et al. 1999. Ebola hemorrhagic fever and pregnancy. J. Infect. Dis. 179(Suppl. 1):S11-12
151. Caluwaerts S, Fautsch T, Lagrou D, Moreau M, Modet Camara A, et al. 2016. Dilemmas in managing pregnant women with Ebola: 2 case reports. Clin. Infect. Dis. 62:903-5
152. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, et al. 2016. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388:498-503
153. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, et al. 2016. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect. Dis. 16:331-38
154. Tiffany A, Vetter P, Mattia J, Dayer JA, Bartsch M, et al. 2016. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin. Infect. Dis. 62:1360-66
155. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, WileyMR, et al. 2015. Molecular evidence of sexual transmission of Ebola virus. N. Engl. J. Med. 373:2448-54
156. Prescott J, Bushmaker T, Fischer R, Miazgowicz K, Judson S, Munster VJ. 2015. Postmortem stability of Ebola virus. Emerg. Infect. Dis. 21:856-59
157. Nordenstedt H, Bah EI, de la Vega MA, Barry M, N'Faly M, et al. 2016. Ebola virus in breast milk in an Ebola virus-positive mother with twin babies, Guinea, 2015. Emerg. Infect. Dis. 22:759-60
158. Mora-Rillo M, ArsuagaM,Ramirez-Olivencia G, Calle F, BorobiaAM, et al. 2015. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patientwithEbola virus disease contracted in Madrid, Spain. Lancet Respir. Med. 3:554-62
159. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, et al. 2007. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 196(Suppl. 2):S142-47
160. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100:446-54
161. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C,Gunther S. 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105:17-21
162. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 2014. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104:153-55
163. Sissoko D, Laouenan C, Folkesson E,M'Lebing AB, Beavogui AH, et al. 2016. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-ofconcept trial in Guinea. PLOS Med. 13:e1001967
164. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, et al. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179(Suppl. 1):S18-23
165. van Griensven J, Edwards T, Lamballerie X, Semple MG, Gallian P, et al. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374:33-42
166. Qiu X, Wong G, Audet J, Bello A, Fernando L, et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53
167. Geisbert TW,Hensley LE, Kagan E, Yu EZ, Geisbert JB, et al. 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193:1650-57
168. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, et al. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896-905
169. Iversen PL, WarrenTK, Wells JB,Garza NL,Mourich DV, et al. 2012. Discovery and early development of AVI-7537 and AVI-7288 for the treatment ofEbola virus andMarburg virus infections. Viruses 4:2806-30
170. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, et al. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402-5
171. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381-85
172. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, et al. 2003. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362:1953-58
173. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, et al. 2007. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J. Infect. Dis. 196(Suppl. 2):S390-99
174. Shuaib F, Gunnala R, Musa EO, Mahoney FJ, Oguntimehin O, et al. 2014. Ebola virus disease outbreak-Nigeria, July-September 2014. Morb. Mortal. Wkly. Rep. 63:867-72
175. Martins KA, Jahrling PB, Bavari S, Kuhn JH. 2016. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev. Vaccines 15:1101-12
176. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, et al. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857-66
177. Routh J. 2015. Study of Ebola survivors opens in Liberia: research to examine long-term health effects of Ebola virus disease. NIAID News Release, June 17. https://www.niaid.nih.gov/news-events/studyebola-survivors-opens-liberia
178. Cent. Dis. Control Prev. 2016. Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Q and A. April 20. http://www.cdc.gov/vhf/ebola/strive/qa.html
179. Leligdowicz A, FischerWA, Uyeki TM. 2016. Ebola virus disease and critical illness. Crit. Care 20:217. https://doi.org/10.1186/s13054-016-1352-2